Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04669886 · ClinicalTrials.gov registry record

Serum Endotoxin Assay to Predict the Development of Postoperative Infectious Complications and Systemic Inflammatory Response Following Percutaneous Nephrolithotomy.

A clinical trial of Nephrolithiasis and Urosepsis, sponsored by University of Miami.

Recruiting
Registry status
150
Enrollment target
1
Study location

NCT04669886 is a study of Nephrolithiasis and Urosepsis that is actively recruiting participants, run by University of Miami. The registered enrollment target is 150 participants, above the 115-participant average among 16 other Nephrolithiasis trials with a reported enrollment target (30% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04669886, a study of Nephrolithiasis and Urosepsis, is actively recruiting participants, sponsored by University of Miami.

RECRUITING
Registry status
150 participants
Enrollment target
1
Study location

Study Summary

The aim of the study is to establish an infectious risk stratification system based on pre-and post-operative blood endotoxin profile.

Study Locations (1)

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2023-11-01
Est. Completion 2026-12-01

Sponsor

University of Miami

721 total trials

What the Registry Record Tells You About NCT04669886

The ClinicalTrials.gov registry entry for NCT04669886 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 115-participant average among 16 other Nephrolithiasis trials with a reported enrollment target (30% higher). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Nephrolithiasis appearing as the primary indexed condition, and to 0 interventions.

NCT04669886 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT04669886 about?

NCT04669886 is a clinical study titled "Serum Endotoxin Assay to Predict the Development of Postoperative Infectious Complications and Systemic Inflammatory Response Following Percutaneous Nephrolithotomy.". The aim of the study is to establish an infectious risk stratification system based on pre-and post-operative blood endotoxin profile.

What is the current status of trial NCT04669886?

This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2023-11-01. Estimated completion is 2026-12-01.

What conditions does trial NCT04669886 study?

This clinical trial studies the following conditions: Nephrolithiasis, Urosepsis.

Who is sponsoring clinical trial NCT04669886?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04669886 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nephrolithiasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.